The global peptide active pharmaceutical ingredient (API) market is experiencing transformational growth, driven primarily by the explosive demand for GLP-1 receptor agonist APIs used in the manufacture of diabetes and obesity drugs — chiefly semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound). According to the Navadhi Global Peptide API Market Strategic Research Report 2026–2031, the market was worth USD 5.15 billion in 2025 and is expected to grow at a CAGR of 15.24% to reach USD 12.05 billion by 2031. Volume growth outpaces value growth substantially: from 265 metric tonnes (MT) in 2025 to 855 MT by 2031 at a 21.72% volume CAGR — reflecting the combination of increased production scale and declining average selling prices as GLP-1 API manufacturing matures and competition intensifies.

The GLP-1 Receptor Agonist API segment is the undisputed market leader at 33.9% share by value in 2026, growing at 22.65% CAGR by value and 32.27% by volume through 2031. By 2031, nearly half of all global peptide API market revenue will derive from GLP-1 products alone, reflecting the massive therapeutic addressable market for obesity and diabetes medications. This extraordinary demand signal — catalysed by the commercial success of Ozempic, Wegovy, Mounjaro, and Zepbound — has triggered one of the most concentrated waves of industrial capacity investment in pharmaceutical history: from Bachem's Building K and Sisslerfeld campus in Switzerland to CordenPharma's EUR 1 billion+ US and Swiss expansion, WuXi TIDES's 100,000+ litre SPPS buildout in China, and PolyPeptide's global capacity additions.

The competitive landscape of this market is fundamentally different from most pharmaceutical markets: it is dominated by specialist contract development and manufacturing organisations (CDMOs) rather than integrated pharmaceutical companies. Bachem and PolyPeptide are the two publicly listed pure-play peptide CDMOs that provide transparent financial benchmarks. CordenPharma, AmbioPharm, Almac, Piramal, CPC Scientific, GL Biochem, and ScinoPharm are either private or list their peptide business as a segment within larger groups. WuXi TIDES operates as a division of the listed WuXi AppTec group. Rankings in this report are based on a composite of revenue scale, SPPS production capacity, GLP-1 API positioning, regulatory qualification breadth, and strategic growth investment.

Note: Rankings are based on a composite of revenue, SPPS production capacity, GLP-1 API positioning, regulatory qualification breadth, and strategic investment scale. Bachem (SIX: BANB) and PolyPeptide (SIX: PPGN) and ScinoPharm (TWSE: 4745) are publicly listed with audited financials. All others are private or report peptide API as a segment within larger groups. Revenue figures are estimates where companies are private. WuXi TIDES is part of listed WuXi AppTec (HKEX/SSE). Piramal Pharma (BSE/NSE) reports total CDMO group revenue inclusive of non-peptide businesses.

• Global peptide API market value (2025): USD 5.15 billion — CAGR 15.24% (2026–2031) → USD 12.05 billion by 2031
• Global peptide API market volume (2025): 265 metric tonnes (MT) — volume CAGR 21.72% → 855 MT by 2031; volume growth substantially outpacing value growth due to manufacturing maturation and ASP decline
• GLP-1 Receptor Agonist API: 33.9% market share by value (2026); CAGR 22.65% value / 32.27% volume — dominant growth engine; semaglutide, liraglutide, tirzepatide the key molecules
• By 2031: ~50% of all global peptide API revenue from GLP-1 products alone
• GLP-1 API growth context: 27.3% YoY growth during 2022–2024 peak; stabilising to 15.2% annually post-2025 as manufacturing matures (not demand slowdown)
• Oncology Peptide API: 15.9% market share (2026); CAGR 12.76% value / 19.71% volume — LHRH analogues for prostate/breast cancer primary driver
• Hormonal Peptide API: 3rd largest; CAGR 9.28% value / 16.48% volume — anchored by long-standing products including oxytocin
• CNS/Neuropeptides and Immunology/Rare Disease: each growing 10%+ annually — pipeline strength beyond obesity
• Asia-Pacific: 38% value market share (2026); highest volume CAGR at 23.19% — WuXi STA 32,000L SPPS (Jan 2024) → >100,000L (2025); GL Biochem and Hybio driving low-cost GLP-1 API scale
• India: 17.97% CAGR — fastest value growth in APAC; Piramal Pharma Solutions (Ambernath) + PolyPeptide India driving growth
• North America: US dominates at 86.4% of regional value share (2026); Bachem California + AmbioPharm South Carolina anchoring premium tier; nearshoring trend accelerating
• Europe: Switzerland = 33.2% of European market (Bachem + PolyPeptide); Germany 15.9% (CordenPharma Frankfurt); France + Belgium + UK 7–10% each
• SPPS (Solid-Phase Peptide Synthesis): dominant technology at ~72% of synthesis market; hybrid SPPS-LPPS growing for complex long-chain sequences
• Consolidation accelerating: Granules India acquired Senn Chemicals (Switzerland) April 2025 — signal of Indian companies targeting European CDMO capabilities
• Bachem gross margin 46.2% — highest among comparable CDMOs; EBITDA margin 29.1% (FY2024); target >30% EBITDA margin with Building K ramp in 2026

Bachem Holding AG (SIX: BANB) is the undisputed global leader in peptide API manufacturing — the world's most profitable, most technically advanced, and most strategically positioned pure-play peptide CDMO. Founded in 1971 by Dr. Peter Grogg in Bubendorf, Switzerland, Bachem has spent over 50 years building a manufacturing and scientific infrastructure that no competitor has yet been able to replicate. Its portfolio encompasses commercial peptide API manufacturing, clinical-stage peptide development (CMC Development), and research chemicals — giving it coverage across the entire peptide product lifecycle from early discovery through to multi-tonne commercial supply.

Bachem's FY2024 revenue of CHF 605.3 million (+4.8% in CHF, +5.6% in local currencies) reflects a year of capacity-constrained growth — the company deliberately prioritised building its next-generation capacity over short-term revenue maximisation. Commercial API grew 5.8% to CHF 327 million, driven by strong patent-protected peptide demand (primarily GLP-1 related). CMC Development grew 3% to CHF 234 million on a strong peptide development project pipeline. The transformational event is Building K: the world's most advanced large-volume peptide and oligonucleotide manufacturing facility, under construction since 2021 at Bubendorf. Equipment commissioning began in late 2024 and first test batches are planned for Q2 2025, with commercial production ramping from H2 2025. Building K is the physical enabler of Bachem's stated target of >CHF 1 billion in annual revenue and >30% EBITDA margin in 2026 — a target that represents a 65%+ revenue growth from 2024 to 2026. In H1 2025, Bachem's momentum was already evident: sales reached CHF 313 million (+30.2% vs H1 2024), with EBITDA margin expanding to 29.1% from 23.1%.

Quick Facts

• HQ: Bubendorf, Basel-Landschaft, Switzerland
• Revenue / Scale: CHF 605.3M (~USD 680M) FY2024 (+4.8%); FY2025: CHF 695M (~USD 775M, +15%); 2026 target: >CHF 1B
• Key Products: GLP-1 API (semaglutide, tirzepatide intermediates), oncology peptides, hormonal peptides, oligonucleotides; Commercial API, CMC Development, Research & Specialties
• Segments: Commercial API (54% of revenue); CMC Development (39%); Research & Specialties (7%)
• 2024–2026 Update: Building K (world's most advanced large-volume peptide plant, Bubendorf) commissioning H1 2025; Sisslerfeld mega-campus under planning; CHF 292M capex FY2024; CHF 332M FY2025; EBITDA margin 29.1%; 2026 target >CHF 1B revenue, >30% EBITDA margin

CordenPharma International is the Western world's most aggressive capacity expander in peptide API manufacturing and the company most likely to challenge Bachem's #1 position by revenue within the 2028–2030 timeframe. Operating as a private company owned by Novacap private equity, CordenPharma is headquartered in Liestal, Switzerland, and operates manufacturing sites across Colorado (USA), Frankfurt (Germany), Caponago (Italy), and Manno (Switzerland). The Colorado facility — inaugurated with a USD 60 million expansion in September 2023 — was already described as the world's largest SPPS facility at the time of opening.

CordenPharma's defining moment came in 2025: a EUR 1 billion-plus strategic investment commitment in peptide development and manufacturing capacity announced at DCAT Week, backed by more than EUR 4 billion in multi-year customer contracts already signed. The Colorado site expansion alone will add 25,000L of SPPS capacity (reaching a total of 42,000L by 2028) — making it larger than Bachem's current Switzerland footprint. In Switzerland, the Basel greenfield site adds a further manufacturing hub. The Frankfurt GMP facility received certification in January 2025 for early-to-mid clinical manufacturing. In March 2025, CordenPharma signed a multi-year strategic partnership with Viking Therapeutics for GLP-1/GIP drug candidate VK2735 — covering peptide API, sterile fill-finish, and oral solid dosage manufacturing. The breadth of this commitment — EUR 4 billion in contracted revenue — is the clearest signal that CordenPharma is building a business designed to reach EUR 1 billion+ in peptide platform revenue by 2028, making it a strong contender to overtake PolyPeptide for the #2 revenue position.

Quick Facts

• HQ: Liestal, Switzerland (HQ); sites in Colorado USA, Frankfurt Germany, Basel Switzerland, Caponago Italy
• Revenue / Scale: ~EUR 400–600M est. (private; targeting >EUR 1B peptide platform by 2028 via EUR 1B+ investment)
• Key Products: Semaglutide API (large-scale SPPS), tirzepatide intermediates, oncology peptide APIs, lipid APIs, oral solid dosage; integrated API-to-drug-product offering
• Segments: Peptide Platform (primary); Lipid Platform; Injectable Platform; Small Molecule Generics
• 2024–2026 Update: EUR 1B+ strategic investment committed (2025 DCAT announcement); Colorado SPPS capacity to 42,000L by 2028 (doubling); EUR 4B+ in multi-year customer contracts secured; Frankfurt GMP certification Jan 2025; CordenPharma-Viking Therapeutics multi-year GLP-1 manufacturing partnership signed Mar 2025

PolyPeptide Group AG (SIX: PPGN) is the world's second-largest pure-play peptide CDMO by revenue and the most direct peer to Bachem in the Swiss-headquartered, European-regulated premium tier. Dating back to 1952 — making it older than Bachem — PolyPeptide has manufactured over 1,000 distinct GMP peptides across its 70+ year history and today serves more than 250 pharmaceutical and biotech customers globally. Its network of six GMP-certified manufacturing sites spans Europe (Strasbourg, France; Malmö, Sweden; Ambernath, India), the US (Torrance, California), and additional European locations — giving it genuine geographic diversification that Bachem's Switzerland-heavy footprint lacks.

PolyPeptide's FY2024 results mark a significant operational recovery: revenue grew 5.1% to EUR 336.8 million, and EBITDA turned sharply positive to EUR 25.4 million (7.5% margin) from a negative EUR 6.0 million in 2023 — driven by improved operational performance, product mix shift toward higher-margin commercial GLP-1 APIs, and reduction of pandemic-related revenue distortions. Commercial revenue grew 8.6%, reflecting solid customer demand and favourable market trends. The company invested EUR 87.8 million in capex (26% of revenue) across its site network to meet strong GLP-1-driven customer demand. Geopolitical considerations — the preference for Western-based CDMOs by European and US pharma companies seeking supply chain sovereignty — are a structural tailwind that PolyPeptide explicitly identifies as a growth driver. Over 100 peptide-based therapies had received FDA approval by end-2024, with approximately 800 synthetic peptide drugs in development, sustaining a deep commercial pipeline for PolyPeptide's CDMO services.

Quick Facts

• HQ: Baar, Zug, Switzerland
• Revenue / Scale: EUR 336.8M (~USD 367M) FY2024 (+5.1% vs 2023); EBITDA EUR 25.4M (7.5% margin, up from -1.8% in 2023)
• Key Products: GLP-1 API (semaglutide, liraglutide), oncology peptides, hormonal peptides (oxytocin), metabolic disease APIs; full-service CDMO from pre-clinical through commercial
• Segments: Commercial (primary, 8.6% growth FY2024); Development (recovering from biotech funding cycle)
• 2024–2026 Update: FY2024 revenue EUR 336.8M (+5.1%); EBITDA recovered to EUR 25.4M (7.5% margin) from negative in 2023; EUR 87.8M capex (26% of revenue) across 6 GMP sites; strong GLP-1 pipeline exposure; geopolitical tailwinds driving demand for Western-based CDMO; 2025 guidance growth acceleration expected

WuXi STA, the small molecule API and peptide manufacturing division of WuXi AppTec, has emerged as the world's largest peptide API manufacturer by production volume, driven by an extraordinary capacity expansion programme that has positioned it as the primary supplier of low-cost, high-volume GLP-1 API to Asian pharmaceutical companies and increasingly to Western generic manufacturers. Operating as WuXi TIDES for its peptide and oligonucleotide operations, the company tripled its SPPS capacity in January 2024 alone by commissioning two new peptide plants — one at Changzhou, one at the new 169-acre Taixing facility — bringing total SPPS reactor volume to 32,490 litres by early 2024 and exceeding 100,000 litres as of 2025.

WuXi TIDES's expansion trajectory is the most dramatic in the global peptide API industry. The 169-acre Taixing mega-site represents one of the largest API manufacturing campuses in the world, with the potential to become the central hub for GLP-1 API supply to Asian markets as semaglutide and tirzepatide biosimilar programmes advance toward commercialisation post-2032 patent expiry. The company supports 48 ongoing preclinical-through-commercial peptide-based therapy programmes. WuXi TIDES also maintains its European manufacturing presence through the Couvet, Switzerland facility, giving it regulatory credibility with Western customers. However, the US BIOSECURE Act — which targeted WuXi AppTec among other Chinese biotech service providers — creates customer concentration risk: US pharma companies have been actively diversifying CDMO relationships away from WuXi-related entities, creating a structural limitation on the company's growth in the US market despite its unmatched cost and scale advantages.

Quick Facts

• HQ: Shanghai, China (part of WuXi AppTec group)
• Revenue / Scale: Part of WuXi AppTec group (total group ~USD 4.8B FY2024); peptide/TIDES segment revenue est. USD 300–500M
• Key Products: Semaglutide API, liraglutide, tirzepatide intermediates, GLP-1 APIs at scale; oncology peptides; oligonucleotides (TIDES platform); preclinical through commercial API manufacturing
• Segments: Peptide API (GLP-1 primary); Oligonucleotides; Small Molecule APIs; Drug Product
• 2024–2026 Update: SPPS capacity grew from 32,000L (Jan 2024) to >100,000L (2025 company website data — most recent) via Changzhou + Taixing plants; 169-acre Taixing mega-site commissioned; Singapore site in development; Middletown DE (USA) planned; supports 48+ peptide-based therapies preclinical through commercial

Hybio Pharmaceutical Co., Ltd. (SZSE: 300199) is China's most important and longest-established listed peptide company, founded in 1998 in Shenzhen and publicly listed on the Shenzhen Stock Exchange since 2011. Hybio distinguishes itself from WuXi TIDES (a CDMO primarily) and GL Biochem (a raw material supplier) through its vertically integrated model: it manufactures peptide APIs, develops peptide formulations, and markets finished peptide drug products — covering the complete chain from synthesis through to patient. This integrated approach has enabled it to obtain the rare distinction of FDA cGMP certification ('zero 483' in the most recent inspection), making it one of the few Chinese peptide companies fully qualified to supply US and European markets.

Hybio's commercial momentum around GLP-1 APIs is accelerating rapidly. The company has approximately 2 million liraglutide injection pens shipped to the US under its FDA-cleared supply chain — a landmark achievement for a Chinese peptide manufacturer. Its August 2025 agreement with 3SBio Mandi to serve as large-scale manufacturer for a semaglutide weight-loss injection for the Chinese domestic market positions it in the highest-growth GLP-1 segment. The July 2025 joint development agreement with iCarbonX for a GLP-1R/GIPR/GCGR triple agonist API places Hybio in the innovative next-generation obesity treatment pipeline alongside Amgen's MariTide — an ambition far beyond traditional CMO positioning. The Ferring Pharma global collaboration adds a reproductive medicine peptide commercial dimension. With a market capitalisation of USD 2.04 billion substantially above its USD 123 million TTM revenue, the market is pricing Hybio's GLP-1 growth optionality at a significant premium.

Quick Facts

• HQ: Shenzhen, Guangdong, China
• Revenue / Scale: ~USD 123M TTM (Pitchbook/Morningstar data); market cap ~USD 2.04B (June 2025)
• Key Products: Liraglutide injection (FDA-approved), semaglutide API and injection (manufacturing partner for 3SBio Mandi weight-loss injection), triptorelin, octreotide, leuprorelin, oxytocin; GLP-1 API export to US/EU
• Segments: GLP-1 APIs & Formulations; Peptide APIs (hormonal, oncology); CMO/CRO Services; Finished Dosage Products
• 2024–2026 Update: FDA zero-483 cGMP inspection pass; ~2 million liraglutide pens shipped to US; semaglutide manufacturing partnership with 3SBio for weight-loss injection signed Aug 2025; GLP-1R/GIPR/GCGR triple agonist API co-development with iCarbonX (Jul 2025); Ferring Pharma global collaboration for reproductive peptides; liraglutide IND/ANDA for US export advancing

AmbioPharm Inc. is the leading US-domiciled pure-play peptide CDMO and the most important domestic supplier of GLP-1 peptide APIs for the North American market — where the report notes the US dominates at 86.4% of regional value share, anchored specifically by AmbioPharm's South Carolina facility alongside Bachem's California sites. Founded in 2001 and headquartered in North Augusta, South Carolina, AmbioPharm operates a dual-site model: its primary GMP manufacturing facility in South Carolina handles commercial and clinical API production using SPPS technology, while its Shanghai, China facility performs process development, optimisation, and large-scale building block synthesis.

AmbioPharm's September 2024 commissioning of its new state-of-the-art South Carolina GMP facility — focused on high-purity peptide APIs for clinical and commercial applications — represents its most significant capacity addition to date. The company committed USD 30+ million to expand total capacity to more than 8 metric tonnes per year, a meaningful step up for a peptide CDMO of its size. AmbioPharm's competitive positioning benefits strongly from the nearshoring trend that the Navadhi report identifies: as US pharma companies seek supply chain sovereignty from China exposure — accelerated by the BIOSECURE Act concerns around WuXi AppTec — AmbioPharm's FDA-inspected US manufacturing facility and its regulatory proximity to FDA reviewers gives it structural advantages that Chinese competitors cannot easily replicate. The company's technical expertise in both SPPS and LPPS (liquid-phase peptide synthesis) for larger, more complex peptide sequences differentiates it from simpler SPPS-only competitors.

Quick Facts

• HQ: North Augusta, South Carolina, USA (primary GMP site); Shanghai, China (process development and building blocks)
• Revenue / Scale: ~USD 36–50M est. (private; North Augusta + Shanghai combined capacity committed to 8+ tonnes/year)
• Key Products: GLP-1 peptide APIs (semaglutide intermediates, tirzepatide building blocks), oxytocin, vasopressin, octreotide, leuprolide, teriparatide, complex custom peptides; FDA/EMA GMP-certified SPPS and LPPS
• Segments: Commercial API (GLP-1 focused); Clinical Development API; Peptide Building Blocks
• 2024–2026 Update: New state-of-the-art South Carolina manufacturing facility launched Sep 2024 — cutting-edge SPPS + purification; USD 30M+ investment commitment to expand total capacity to >8 tonnes/year; US regulatory proximity a key advantage vs Asian competitors amid nearshoring trend; CombiGene partnership for pain peptide COZY01 (2023)

ScinoPharm Taiwan Ltd. (TWSE: 4745) occupies a strategically important position in the global peptide API market as the leading Taiwanese manufacturer combining small-molecule oncology API expertise with a growing peptide synthesis capability. Headquartered in the Tainan Science Park in southern Taiwan, ScinoPharm has built a global reputation for producing high-quality APIs for cancer treatment — particularly complex oncology peptides, GnRH agonists and antagonists, and somatostatin analogues — which have passed quality inspections from Taiwan FDA, US FDA, EU EMA/EDQM, Australian TGA, Japanese PMDA, Korean FDA, and German authorities.

ScinoPharm's regulatory qualification across all major global markets is its most valuable competitive asset: very few Asian API manufacturers can show simultaneous FDA, EMA, TGA, PMDA, and Korean MFDS compliance. This multi-regulatory standing enables it to supply API to partners in North America, Europe, and Asia-Pacific simultaneously — a capability that directly addresses the supply chain diversification imperative that Western pharma companies have been pursuing since 2020. In the context of the Navadhi report's emphasis on GLP-1 APIs as the market's primary growth driver at 22.65% CAGR, ScinoPharm is in the early stages of building GLP-1 API development capabilities alongside its established oncology peptide core. Taiwan's strategic location — outside the US BIOSECURE Act's direct scope — gives it a geopolitical positioning advantage over Chinese competitors for US market supply.

Quick Facts

• HQ: Tainan Science Park, Taiwan
• Revenue / Scale: ~TWD 3–4B est. FY2024 (~USD 95–125M; listed on TWSE with public financials)
• Key Products: Oncology peptide APIs (paclitaxel analogues, GnRH agonists/antagonists), hormonal peptides, somatostatin analogues, GLP-1 adjacent APIs; established HPLC purification and analytical capabilities
• Segments: Oncology APIs (primary); Hormonal/Metabolic APIs; Specialty Peptides; Generic API Development
• 2024–2026 Update: Robust API business performance reported Aug 2024; TWSE-listed providing transparency; Taiwan's regulatory bridge between Asian manufacturing and Western FDA/EMA qualification; expanding peptide capabilities alongside established small molecule oncology core; GLP-1 API development programme building

Almac Group is a privately-owned Irish life sciences company headquartered in Craigavon, Northern Ireland, whose Almac Sciences division is one of Europe's most technically sophisticated peptide CDMO operators. Founded in 1968 as Almac (Northern Ireland) Ltd., the group has evolved into a comprehensive drug development services company spanning discovery, clinical development, drug substance manufacturing, and drug product supply. Its peptide manufacturing capabilities are housed within Almac Sciences, which provides SPPS and LPPS peptide API services, conjugation chemistry (for peptide-drug conjugates and radiopharmaceuticals), and potent compound manufacturing in containment-rated facilities.

Almac's competitive differentiation lies in its specialisation in complex, high-value peptide sequences that require capabilities beyond standard SPPS: cyclic peptides, stapled peptides, PEGylated peptides, and increasingly peptide-drug conjugates (PDCs). These complex modalities command significantly higher manufacturing margins than commodity GLP-1 API and represent the highest-growth subsegment of the peptide API market — where the Navadhi report notes CNS/neuropeptides and immunology/rare disease segments are each expanding at 10%+ annually. Almac's Northern Ireland location gives it a dual regulatory gateway: FDA compliance for the US market and MHRA/EMA compliance for the European market — the latter gained importance post-Brexit as Northern Ireland maintained EMA-aligned regulatory status. The group's integrated drug development services create natural CDMO customer retention: companies that use Almac for drug discovery and clinical development services are predisposed to continue with Almac Sciences for API manufacturing, reducing competitive attrition.

Quick Facts

• HQ: Craigavon, Northern Ireland, UK
• Revenue / Scale: ~GBP 700–800M est. total Almac Group FY2024 (private; peptide sciences division est. GBP 80–120M)
• Key Products: Peptide APIs (complex sequences, cyclic peptides, stapled peptides), oligonucleotides, peptide-drug conjugates (PDC), radiopharmaceuticals, potent compound handling; SPPS + LPPS capabilities
• Segments: Peptide Sciences (API manufacturing); Drug Discovery; Clinical Services; Drug Product Manufacturing; Radiopharmaceuticals
• 2024–2026 Update: Northern Ireland facility cited as critical European/UK peptide CDMO capacity; complex peptide specialisation (cyclic, stapled, PDC) commanding premium pricing; potent compound handling expertise serving ADC/PDC high-growth segment; regulatory access to both FDA (US) and MHRA (UK)/EMA (EU) post-Brexit

Piramal Pharma Solutions is India's most strategically important peptide API manufacturer and the company that the Navadhi report specifically names as the anchor of India's emergence as the fastest-growing peptide API sub-market in Asia-Pacific at 17.97% CAGR. Piramal Pharma Limited (BSE/NSE: PIRPHARMA) is a publicly listed Indian pharmaceutical and CDMO group that has built a world-class CDMO infrastructure spanning its Ambernath, Grangemouth, Riverview, and multiple other sites globally. Its Ambernath site in Maharashtra is the designated home of its peptide API capabilities — specifically its solid-phase peptide synthesis facility for semaglutide and other GLP-1 API manufacturing.

Piramal Pharma's FY2025 consolidated revenues of approximately INR 8,949 crore (approximately USD 1.07 billion) demonstrate the scale of its broader CDMO platform, within which peptide API is a growing but not yet dominant component. The company's positioning in peptide API is built on its Indian cost structure — giving it a manufacturing cost advantage versus European CDMOs — combined with FDA, EMA, and other regulatory qualifications that allow it to supply Western customers. India's CAGR of 17.97% in peptide API is driven precisely by this model: Indian manufacturers leveraging regulatory compliance with Western pricing discipline to capture outsourcing from European and American pharma companies seeking supply chain diversification away from China. Granules India's April 2025 acquisition of Senn Chemicals (Switzerland) — a deal that signals Indian companies targeting European peptide CDMO capabilities — validates the strategic direction that Piramal has been pursuing organically.

Quick Facts

• HQ: Mumbai, Maharashtra, India
• Revenue / Scale: INR 8,949 crore (~USD 1.07B) FY2025 total Piramal Pharma (consolidated); peptide/CDMO segment est. USD 150–200M
• Key Products: GLP-1 API (semaglutide API via Ambernath SPPS facility), hormonal peptides, oncology peptides, antibody-drug conjugate intermediates; CDMO services across HPAPI, injectables, oral solid dosage
• Segments: CDMO Services (global; API + drug product); India Branded Generics; Critical Care
• 2024–2026 Update: Ambernath (Maharashtra) peptide SPPS facility: India's flagship peptide API site; India fastest-growing APAC sub-market at 17.97% CAGR; FY2025 revenue INR 8,949 crore; CDMO client base includes global big pharma for semaglutide API supply; positioned as premier Indian peptide CDMO for Western outsourcing

The 10th position in the global peptide API ranking is shared by two distinct but complementary companies that together represent the US specialty CDMO tier (CPC Scientific) and the China-based peptide raw materials and bulk supply tier (GL Biochem). CPC Scientific Inc., headquartered in Sunnyvale, California, is a full-service GMP peptide manufacturer with eight GMP production sites globally — one of the broadest manufacturing footprints in the industry for a company of its size — serving the pharmaceutical and biotech industry from research peptides through commercial GMP API. GL Biochem (Shanghai) Ltd. is a Shanghai-based manufacturer of peptide raw materials, Fmoc-protected amino acids, resin components, and bulk research and commercial-grade peptides that form the substrate inputs for SPPS manufacturing globally.

CPC Scientific's scale — eight GMP sites — gives it unusual geographic diversification for a private specialty CDMO, enabling it to serve multiple regulatory jurisdictions from sites in the US, China, and elsewhere. Its specialty in cyclic, lipidated, and long-chain peptides positions it in the highest-complexity, highest-margin product categories. According to the LCGC data cited in the Navadhi report, CPC has plans for a new manufacturing facility that will further expand its commercial GMP capacity. GL Biochem operates at a different but strategically critical layer: as the supplier of the Fmoc amino acid building blocks and peptide raw materials that feed the SPPS manufacturing process at Bachem, PolyPeptide, WuXi, and others. As GLP-1 API production scales globally from 265 metric tonnes (2025) to a projected 855 metric tonnes (2031) — a 3.2× volume increase — the demand for GL Biochem's raw material supply will scale proportionally, making it a critical infrastructure node in the global peptide API supply chain even if it never appears on a CDMO client list.

Quick Facts

• HQ: CPC: Sunnyvale, California, USA; GL Biochem: Shanghai, China
• Revenue / Scale: CPC: ~USD 36M est. (private); GL Biochem: ~USD 80–120M est. (private; large-scale bulk peptide supplier)
• Key Products: CPC: Custom GMP peptides (research through commercial), cyclic peptides, lipidated peptides, long-chain peptides; GL Biochem: Bulk peptide raw materials, Fmoc amino acids, peptide building blocks, research-grade peptides at scale; both serve GLP-1 supply chain
• Segments: CPC: Commercial GMP peptide API; GL Biochem: Raw materials, building blocks, research-scale through tonne-scale bulk supply
• 2024–2026 Update: CPC: 8 GMP production sites globally; new manufacturing facility planned per LCGC data; strong US West Coast presence; GL Biochem: Critical supplier of Fmoc amino acids and peptide building blocks that feed the global SPPS supply chain; supports WuXi, Bachem, and other CDMOs' raw material needs; low-cost China manufacturing base

• GLP-1 demand triggered the largest capacity investment wave in peptide API history (2022–2026): The commercial success of semaglutide and tirzepatide has triggered capital investment commitments exceeding USD 3 billion collectively across the top 5 peptide CDMOs — Bachem (CHF 292M capex FY2024 + CHF 332M FY2025 + CHF 400M+ FY2025 plans), CordenPharma (EUR 1B+), PolyPeptide (EUR 87.8M FY2024), WuXi TIDES (massive China buildout), and AmbioPharm (USD 30M+). This represents a structural transformation of the supply side of a market that had been capacity-constrained for years.
• BIOSECURE Act created Western supply chain realignment: US Congressional attention to WuXi AppTec and other Chinese CDMOs through the proposed BIOSECURE Act (2024) triggered a wave of US pharma company CDMO diversification away from Chinese suppliers. While WuXi TIDES remained the dominant volume player, Bachem, CordenPharma, AmbioPharm, and PolyPeptide all reported increased RFP activity from US clients seeking Western supply chain alternatives — a structural tailwind that the report identifies as geopolitical considerations driving demand for Western CDMOs.
• Volume CAGR (21.72%) substantially exceeding value CAGR (15.24%) signals ASP compression: As GLP-1 API manufacturing scales and matures, average selling prices are declining — a dynamic the report specifically notes. Chinese manufacturers (WuXi TIDES, GL Biochem, Hybio) are the primary drivers of volume growth at lower ASPs, while Western manufacturers (Bachem, CordenPharma) are defending margins through quality premium, regulatory compliance, and complex molecule specialisation.
• Granules India's acquisition of Senn Chemicals AG (April 2025): A landmark deal signalling Indian pharmaceutical companies' ambition to enter the European peptide CDMO market through acquisition rather than organic capability building. Senn Chemicals, a Swiss peptide CDMO, gives Granules India immediate Swiss GMP manufacturing credentials, regulatory relationships, and customer access — precisely the geographically and regulatorily differentiated position that Piramal has been building organically.
• Building K at Bachem Bubendorf represents a generational capacity step-change: Bachem's Building K — the world's most advanced large-volume peptide and oligonucleotide manufacturing facility — commenced equipment commissioning in late 2024 with first test batches planned Q2 2025. This single facility is designed to more than double Bachem's commercial API production capacity, enabling the CHF 1 billion+ revenue target for 2026. No comparable capacity addition at a single facility has occurred in the Western peptide manufacturing sector since the GLP-1 boom began.
• CordenPharma's EUR 4B+ contracted revenue backlog redefines CDMO business model: CordenPharma's announcement of EUR 4 billion in multi-year customer contracts — the revenue committed but not yet delivered — establishes a contracted backlog model that eliminates demand uncertainty and enables massive fixed capital investment with predictable returns. This approach mirrors the business model transformation that CDMOs in the biologics sector (Lonza, Samsung Biologics) implemented with monoclonal antibody manufacturing, now being replicated in peptides.

If you want to assess the growth trajectory of the global peptide market, the Global Peptide Market Strategic Intelligence Suite 2026-2031 offers a definitive analysis of market dynamics, competitive landscapes, and technological shifts through 2031. It provides key insights into the GLP-1 segment, Peptide API manufacturing trends, and emerging therapeutic applications to help you identify high-value investment opportunities and optimize your market entry strategy.

1. The GLP-1 Capacity Race — From 265 MT to 855 MT by 2031

The peptide API volume market will grow from 265 metric tonnes in 2025 to 855 metric tonnes by 2031 — a 3.2× increase in just six years. This extraordinary volume expansion is almost entirely driven by GLP-1 API (semaglutide, tirzepatide, liraglutide), whose volume CAGR of 32.27% through 2031 implies that GLP-1 API production alone will grow from approximately 90 MT today to potentially 400+ MT by 2031. The industry has never experienced this rate of volume growth for a single peptide drug class. The response — hundreds of billions in manufacturing capex globally — is reshaping the physical infrastructure of pharmaceutical chemistry.

2. Western vs. Eastern Supply Chain Bifurcation

The peptide API market is bifurcating into two distinct competitive tiers: a Western premium tier (Bachem, CordenPharma, PolyPeptide, AmbioPharm) commanding price premiums of 30–50% for FDA/EMA-qualified GMP manufacturing, intellectual property protection, and supply chain sovereignty; and an Eastern volume tier (WuXi TIDES, GL Biochem, Hybio) offering significant cost advantages and increasingly compliant quality systems. The geopolitical environment — US BIOSECURE Act discussions, EU supply chain diversification mandates, and post-pandemic pharmaceutical sovereignty initiatives — is driving structural investment in the Western tier that would not occur on market economics alone.

3. SPPS Technology Scale-Up Breaking Previous Physical Constraints

Solid-Phase Peptide Synthesis (SPPS) — the dominant manufacturing technology for GLP-1 API — was historically limited to kilogram-scale production. The capacity expansion wave of 2022–2025 has broken this constraint: WuXi TIDES now has >100,000L of SPPS reactor volume (from approximately 10,000L in 2021); CordenPharma's Colorado facility will reach 42,000L by 2028; and Bachem's Building K adds multi-tonne commercial SPPS at a scale previously unprecedented. These investments are compressing production costs and enabling the volume expansion needed to supply a global GLP-1 drug market that may exceed USD 100 billion by 2030.

4. India Emerging as Both Demand and Supply Hub

India's 17.97% CAGR in the peptide API market reflects a dual role: growing domestic demand for GLP-1 therapies as the Indian middle class expands and diabetes prevalence rises, and growing supply capacity as Indian CDMOs (Piramal, Granules, Divi's) build GLP-1 API manufacturing capabilities targeting both domestic biosimilar market needs and Western export markets. The April 2025 Granules India acquisition of Senn Chemicals gives Indian industry Swiss manufacturing credibility. India's biosimilar pharmaceutical industry is already preparing for the semaglutide patent expiry in 2032, making Indian peptide API capacity an existential requirement of that strategic bet.

5. Complex Peptide Modalities and Conjugates as Premium Growth Vectors

While commodity GLP-1 API is the volume growth story, the highest-margin growth vector in peptide API is the convergence with complex modalities: peptide-drug conjugates (PDCs), stapled peptides, cyclic peptides, PEGylated peptides, and radioligand therapy peptide targeting vectors. These complex molecules command ASPs 5–20× higher than GLP-1 API and require manufacturing expertise that only a handful of CDMOs possess — Bachem, Almac, CordenPharma (through its lipid platform), and CPC Scientific. As the oncology peptide segment grows at 12.76% CAGR and CNS/neuropeptide and immunology/rare disease segments each grow at 10%+ annually, these high-value complex modalities will become an increasingly important revenue source for the most technically advanced manufacturers.